Table 2.
Biochemical and clinical toxicities after Y-90 radioembolization, evaluated at 3 months posttreatment.
| Biochemical and clinical toxicities | Number of patients (%) |
|---|---|
| ALT (U/L) | |
| Grade 1 | 2 (4%) |
| Grade 2 | 0 |
| Grade 3 | 1 (2%) |
| Grade 4 | 0 |
|
| |
| AST (U/L) | |
| Grade 1 | 11 (22%) |
| Grade 2 | 1 (2%) |
| Grade 3 | 1 (2%) |
| Grade 4 | 0 |
|
| |
| ALP (U/L) | |
| Grade 1 | 26 (53%) |
| Grade 2 | 3 (6%) |
| Grade 3 | 0 |
| Grade 4 | 1 (2%) |
|
| |
| WBC | |
| Grade 1 toxicity | 4 (8%) |
| Grade 2 toxicity | 1 (2%) |
| Grade 3 | 0 |
| Grade 4 | 0 |
|
| |
| Bilirubin (μmol/L) | |
| Grade 1 toxicity | 5 (10%) |
| Grade 2 toxicity | 0 |
| Grade 3 | 0 |
| Grade 4 | 0 |
|
| |
| Clinical toxicities | |
| Fatigue, grade 1 | 2 (4%) |
| Abdominal pain, grade 3 | 3 (6%) |
| Gastric ulceration, grade 1 | 1 (2%) |
| Odynophagia, grade 1 | 1 (2%) |
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase.